Objectives: To stepwise select tigecycline-resistant Escherichia coli mutants in vitro, determine the mutation rates, identify the resistance mechanisms, determine the resistance level and cross-resistance to other antibiotic classes, evaluate the fitness costs of tigecycline resistance mechanisms and investigate if the same in vitro-identified target genes were mutated in clinical isolates.
Introduction
The minocycline derivative tigecycline is the first medically approved representative of a new group of tetracycline antibiotics called glycylcyclines. 1, 2 Tigecycline is a broad-spectrum bacteriostatic antimicrobial compound that binds to the ribosomal A site of the 30S subunit and interferes with translation. 3 -5 It is active against pathogens such as methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, vancomycinresistant enterococci and extended-spectrum b-lactamase (ESBL) producers. 6 In addition, it is one of the last-resort drugs to treat bacteria expressing New Delhi metallo-b-lactamase-1 (NDM-1). 7 The American FDA approved the use of tigecycline in 2005 and the European Medicines Agency in 2006 for the treatment of adult complicated skin and skin structure infections and complicated intra-abdominal infections. 8, 9 In 2008, the FDA additionally approved the usage of tigecycline for community-acquired pneumonia. 10 Tigecycline was developed to overcome the main tetracycline resistance mechanisms, efflux and ribosomal protection mediated by Tet proteins. 11 Although tigecycline can induce the expression of the Tet(B) pump, 12 evasion of efflux is probably conferred by the bulky 9-t-butylglycylamido group, which prevents tigecycline from being recognized as an efflux pump substrate. A similar effect was observed for the earlier glycylcycline 9-(N,N-dimethylglycylamido)-6-demethyl-6-deoxytetracycline (DMG-DMDOT). 13 It seems that in addition to the stronger binding to ribosomes, the same side chain of tigecycline is responsible for escaping the protection of ribosomes by Tet proteins. 4 Recent structural studies demonstrated that the 9-t-butylglycylamido group, once the drug is bound to the ribosome, prevents the correct interaction between 16S rRNA and the loop III of domain IV of the Tet(M) protein. 5, 14 The first reports about clinical tigecycline resistance were published soon after its introduction into medical practice. In most cases, the emerging resistance was reported in the Gram-negative # The Author 2013. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2013; 68: 2809 -2819 doi:10.1093/jac/dkt263 Advance Access publication 9 July 2013 pathogens Acinetobacter baumannii, Klebsiella pneumoniae, Enterobacter spp. and Bacteroides fragilis, with Enterococcus faecalis being a Gram-positive exception. 1, 2, 15 Some bacteria, such as Pseudomonas aeruginosa, Proteus spp. Providencia spp. and Morganella spp., are naturally less susceptible to tigecycline. 1,3 -5 In most of the cases, it is due to the constitutive expression of resistancenodulation-division (RND) efflux pumps: MexXY-OprM in P. aeruginosa, 6, 16 AcrAB in Proteus mirabilis 7, 17 and Morganella morganii. 8, 9, 18 Additionally, RND pumps are connected to reduced susceptibility to tigecycline in K. pneumoniae, 10, 19 Enterobacter cloacae, 11, 20 Escherichia coli, 12,21 Salmonella enterica 13, 22 and Acinetobacter spp. 4, 23, 24 Overexpression of the MATE family efflux pump MepA is suggested as the reason behind decreased susceptibility to tigecycline in S. aureus. 5, 14, 25 Similarly, efflux pumps are related to tigecycline resistance in Burkholderia spp. 26 The first enzymatic degradation tigecycline resistance mechanism conferred by Tet(X) was initially found in the anaerobic bacterium B. fragilis. 27 This enzyme is a flavindependent monooxygenase that hydroxylates tigecycline, highly reducing its antibacterial activity. This enzyme has not been found in any clinically relevant pathogens yet, but its presence on mobile elements could potentially cause the spread of tigecycline resistance from Bacteroides to other anaerobic and aerobic bacteria. 28 E. coli is one of the dominant causes of intra-abdominal and skin and skin structure infections worldwide. 29, 30 It is especially worrying as ESBL-and carbapenemase-producing E. coli have emerged during recent years, reducing the treatment options 31, 32 and, in the case of NDM-1, colistin and tigecycline are left as the last-resort drugs. 7 In Europe, resistance to tigecycline in E. coli is very low. Some isolates collected during the Tigecycline Evaluation Surveillance Trial demonstrate increased tigecycline MICs in a few European countries. 33 The clinical resistance interpretation is slightly complicated due to different MIC breakpoints set by EUCAST (≤1 mg/L, susceptible; .2 mg/L, resistant) and the FDA (≤2 mg/L, susceptible; ≥8 mg/L, resistant). 34, 35 Previous studies suggest that antibiotic resistance is frequently associated with a biological fitness cost for bacteria, expressed as, e.g. reduced growth rates, lower virulence or decreased transmission. 36, 37 However, processes such as compensatory evolution, cost-free resistance and coselection between the resistance mechanism and other selected markers can affect the dynamics of bacterial spread within the population, with and without antibiotic pressure, and sometimes allow the resistance mechanism to establish itself in a bacterial population. Therefore, it is of high importance to evaluate this cost in order to understand the development of antibiotic resistance.
Information about in vitro tigecycline-resistant mutants is scarce. In this study, we characterized in vitro-selected E. coli strains with reduced susceptibility to tigecycline and evaluated their biological fitness and cross-resistance. Our results suggest that it is relatively difficult to isolate E. coli mutants that are resistant to high levels of tigecycline in vitro and the high fitness cost of mutations is likely to reduce the ability of resistant mutants to establish a successful infection.
Methods

Clinical strains
Eight clinical E. coli isolates with reduced susceptibility to tigecycline were obtained from Uppsala University Hospital (DA21682, DA24439, DA24486 and DA24516), the Swedish Institute for Communicable Disease Control (DA25176 and DA25177) and the Clinical Microbiology Laboratory, Vä xjö Hospital (DA26668 and DA26669). The bacteria were isolated during routine screenings of samples between 2010 and 2012.
In vitro selection of tigecycline mutants with reduced susceptibility E. coli mutants with decreased susceptibility to tigecycline were selected by plating 40 independent cultures (each inoculated with 10 3 cfu) of the E. coli MG1655 strain (DA5438) on Mueller-Hinton (MH) growth medium (Difco) supplemented with 1.5% agar (Oxoid) containing 0.19 mg/L tigecycline (Wyeth). The MIC of tigecycline for E. coli MG1655 was 0.047 mg/L. The mutants (one per independent culture) were randomly picked after 24 and 48 h of incubation at 378C and reisolated on plates with the same concentration of tigecycline. A subsequent isolation step was performed on MH agar plates without selection and the colonies were resuspended in MH broth and frozen with 10% sterile DMSO. Secondstep mutants were selected by plating 10 independent cultures of firststep mutants (DA19140, DA19153 and DA19165) on MH agar plates with 2× and 4× the tigecycline MIC of the corresponding first-step mutant. Selection experiments were repeated at least twice for each strain. Mutation rates for acquiring mutations reducing susceptibility to tigecycline were calculated using the median method of Lea and Coulson. 38 
Determination of MICs
MICs for all mutants were determined using Etest strips (bioMérieux). A culture was incubated in a shaking incubator (190 rpm) at 378C overnight and then diluted 1000-fold in 0.9% NaCl (w/v) solution. The diluted suspension was distributed on an MH agar plate with a cotton swab. An Etest strip was applied and the plate was incubated at 378C for 16 -20 h. The MIC was read as the lowest concentration at which no bacterial growth was observed.
Determination of growth parameters
The growth characteristics of the mutants were measured in MH broth at 378C by taking optical density at 600 nm (OD 600 ) measurements every 4 min in a BioscreenC reader (Oy Growth Curves Ab Ltd). Three independent cultures per mutant were grown overnight until saturation. The cultures were diluted to 5×10 6 cfu/mL and aliquotted into a BioscreenC plate in quadruplicate (0.3 mL/well). The time to reach an OD 600 of 0.01 during the growth experiment was operationally defined as the time that the bacterial strain spent in the lag phase. The growth rate was estimated from the OD 600 interval between 0.02 and 0.08, where the growth was observed to be exponential. The OD 600 value after 16 h of growth, when bacteria reached the plateau in the stationary phase, was set to be the total yield. Relative values for each parameter were calculated by dividing the corresponding parameter of the mutant by the average corresponding parameter of an otherwise isogenic wild-type strain in the same experiment.
Sanger sequencing
Target genes were PCR amplified with primers binding upstream and downstream of the coding region using AmpliTaq Gold DNA polymerase (Applied Biosystems). PCR products were purified with the GeneJet Gel Extraction Kit (Thermo Scientific) and pre-mixed with one of the amplification primers. The mixture was dried with a centrifugal evaporator and sent to Eurofins MWG Operon (Ebersberg, Germany) for Sanger sequencing. The primers are listed in Table 1 .
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Whole-genome sequencing
The genomes of selected mutants were prepared using QIAGEN Genomictip 100/G columns and the Genomic DNA Buffer Set (QIAGEN) according to the manufacturer's recommendations and sent to the BGI sequencing facility (Hong Kong, China). Genomes were sequenced using Illumina sequencing technology with 500 bp paired-end libraries. Genomes were sequenced in batches: sequencing of the first batch of mutants generated 12000000 reads with 250× genome coverage, the second batch of mutants returned 4500000 reads with 90×genome coverage and the clinical isolates produced 11000000 reads with 200× genome coverage. Whole-genome data were analysed with CLC Genomics Workbench 6.0.1 (CLC Bio). Illumina paired-end reads of each isolate were individually mapped onto the wild-type reference genome of E. coli K-12 MG1655 sequenced earlier in our laboratory. Single nucleotide polymorphisms (SNPs) and larger genome rearrangements were detected using CLC Genomics Workbench 6.0.1 (CLC Bio) built-in Probabilistic Variant Detection and Structural Variant tools, respectively, with standard settings.
Bioinformatic analysis of E. coli sequences to identify potential mutations decreasing tigecycline susceptibility in the clinical isolates
In order to identify potential changes in mutated target genes responsible for the reduced susceptibility to tigecycline in clinical isolates, a comparison of target amino acid sequence variability was performed. Eighteen genomes of different E. coli strains (AE014075, CP000819, CP000946, CP000970, CP001164, CP001509, CP001637, CP001665, CP001671, CP001855, CP001969, CP002516, CP002167, NC_000913, NC_002695, NC_004431, NC_013353 and NC_013361) were obtained from the National Center for Biotechnology Information (NCBI). Target gene sequences were extracted from all 18 genomes, translated and aligned using CLC Main Workbench 6.8.2 (CLC Bio) nucleotide analysis and alignment tools with standard settings. Conserved and variable regions of targets identified in mutants selected in vitro were determined from the alignments. The amino acid sequence changes in potential targets of clinical isolates were considered significant only if they were found in highly conserved regions.
Susceptibility to novobiocin
Mutants with impaired heptose biosynthesis are known to be hypersusceptible to novobiocin. 39 Overnight cultures of mutant strains with reduced susceptibility to tigecycline and parental wild-type controls were serially diluted and 5×10 6 cfu of bacteria were inoculated into 1 mL of MH broth supplemented with 200, 6.25 or 1.6 mg/L novobiocin. The bacterial suspension was aliquotted in a BioscreenC plate (0.25 mL/well) in triplicate and incubated at 378C for 16 h with shaking. The growth of the mutants was evaluated by taking OD 600 measurements every 4 min in a BioscreenC reader (Oy Growth Curves Ab Ltd).
Reconstruction of mutations
Mutations in genes responsible for decreased susceptibility to tigecycline were moved to the wild-type strain DA5438 using Lambda Red recombineering. 40, 41 A neo resistance marker flanked by flippase (Flp) recognition target (Frt) sites was amplified with Phusion High-Fidelity DNA Polymerase (Thermo Scientific) from template plasmid pKD4 (accession number AY048743) with primers containing 40 bp homology for intergenic regions linked to the mutated genes. The resistance marker with the linked mutation of interest was transferred from mutant strains to DA5438 by P1 transduction. The neo cassette was removed by Flp recombination. If P1 transduction of mutants was not possible, two-step Lambda Red recombineering was performed. A neo-ccdB cassette was amplified from the pKD45 plasmid template (a gift from Diarmaid Hughes) with homology sites to the target genes and inserted during the first Lambda Red recombination step. The PCR product of the mutated gene was used to exchange the inserted neo-ccdB cassette during the second Lambda Red recombination step. All reconstructed mutations were confirmed by PCR and sequencing.
Stationary-phase survival assay
Three independent cultures of reconstructed mutants were incubated in MH broth at 378C with shaking (190 rpm) for 1 week to evaluate the mutant growth in prolonged stationary phase. Viable counts were performed at four timepoints (days 1, 2, 4 and 7) by plating bacteria on Luria agar plates. The data were normalized to the cfu/mL of day 1.
Results
In vitro selection of E. coli mutants with reduced susceptibility to tigecycline
We selected in vitro E. coli mutants with decreased susceptibility to tigecycline compared with the parental wild-type (DA5438). Firststep mutants were isolated on plates supplemented with 0.19 mg/L of tigecycline by plating 40 independent cultures. Mutation rates for these mutants with reduced susceptibility to tigecycline ranged between 5.6×10 28 and 5.5×10 27 per cell per generation. We also tried selecting the first-step mutants on higher concentrations of tigecycline (0.75 mg/L and 3 mg/L), but unsuccessfully even after plating up to 10 11 cfu in total (40 independent cultures with 3×10 9 cfu from each culture were plated). After the first-step selections, we chose three different first-step mutants (DA19140, DA19153 and DA19165) with varying tigecycline MICs as parental strains for the second-step selections. Second-step mutants were selected by plating 10 independent cultures of each mutant strain on 2× and 4× the tigecycline MIC of the corresponding first-step mutant. The mutation rates for mutants causing increased tigecycline MICs varied from 7.5×10 29 to 1.7×10 26 per cell per generation. Attempts to isolate third-step mutants with even higher tigecycline MICs on 2×, 4× and 8× the MIC of the respective parental strains were unsuccessful. No mutants were obtained from four different parental second-step strains with 10 -60 independent cultures per strain (3×10 9 cfu plated per culture). 
Mechanisms of tigecycline resistance 2811 JAC Identification of potential target genes responsible for reduced susceptibility to tigecycline A set of selected first-and second-step mutants was wholegenome sequenced to identify the resistance determinants responsible for decreased susceptibility to tigecycline. Analysis of the whole-genome sequencing data allowed us to group the mutants into two distinct groups (Table 2) . We assigned all the mutants carrying mutations in efflux regulatory genes to the efflux regulatory network (ERN) group. The mutations belonging to this group were present in the local regulator AcrR, controlling AcrAB efflux pump expression, the local regulator MarR, modulating global transcriptional regulator MarA, and Lon protease. Another group of mutations that affected the lipopolysaccharide biosynthesis pathway was named the LPS group. All the genes in this group were involved in heptose biosynthesis (lpcA, rfaE and rfaD) and transport (rfaC and rfaF).
The main SNPs observed were nucleotide substitutions causing amino acid changes and nucleotide insertions or deletions resulting in frame shifts in protein-coding sequences. In addition to SNPs, insertion sequence (IS) elements were involved in genome rearrangements. IS1 elements were found to disrupt the function of acrR (three isolates) and rfaD (one isolate) genes, and IS2 had inserted into the coding sequence of the rfaF (one isolate) gene. Five first-step mutants had IS186 inserted in the promoter region of Lon protease. It was shown previously that the lon promoter sequence is a hot spot for IS186 insertion. 42 -44 Interestingly, the majority of first-step mutants from the ERN group had an inactivated lon gene. Moreover, IS elements were involved not only in disrupting the open reading frames (ORFs) of genes, but also in the recombination events causing duplications of certain regions. Two different duplications were detected among the second-step LPS mutants. One was flanked by IS3 elements ( 252 kb; two isolates), and the second one was flanked by IS5 elements ( 415 kb; two isolates). Both duplications included the AcrAB efflux system. These duplications were acquired as the second mutation further reducing the susceptibility to tigecycline. Duplications of the chromosomal region containing the acrAB genes were previously identified in E. coli mutants selected on low concentrations of tetracycline. 44 
Characterization of in vitro-selected and reconstructed mutants
The MIC of tigecycline for the E. coli MG1655 strain (DA5438) used as a starting strain for the first-step in vitro mutant selection was 0.047 mg/L. Tigecycline MICs for the first-step mutants ranged from 0.094 to 0.25 mg/L, with a median value of 0.125 mg/L ( Table 2 ). The first-step mutants from the ERN group displayed slightly higher values compared with the LPS group. The secondstep mutants demonstrated tigecycline MICs from 0.19 to 0.75 mg/L, with a median of 0.5 mg/L ( Table 2 ). The same tendency of slightly higher MICs was observed in the second-step ERN strains. Tigecycline clinical breakpoints set by EUCAST are .1 mg/L for intermediate and .2 mg/L for resistant isolates. 35 Therefore, clinical resistance was not reached in our two-step selection experiments. Reconstruction of putative target mutations in the wild-type background confirmed that lon, marR, rfaC, rfaE and lpcA mutations played a role in reduced susceptibility to tigecycline, as all strains had elevated MICs compared with the wildtype control (Table 3 ). The MIC values between reconstructed strains of ERN and LPS groups were almost identical, with the majority of strains exhibiting MICs of 0.125 mg/L. Some of the whole-genome-sequenced mutants had additional genomic changes compared with the reference strain ( Table 2) . A few of these mutations (phnK and rhtB) were also transferred into the wild-type background and found not to contribute to the reduced susceptibility to tigecycline (data not shown).
Next, we checked if the original and reconstructed mutants with reduced susceptibility to tigecycline exhibited increased MICs of other antibiotics. We tested eight different antibiotics representing several major classes of drugs: tetracycline, chloramphenicol, kanamycin, erythromycin, ampicillin, cefotaxime, ciprofloxacin and nitrofurantoin (Table 3) .
Original mutants
Interestingly, the MICvalues of more hydrophobic antibiotics such as chloramphenicol and erythromycin followed the division of the mutants into two distinct groups. The ERN group mutants were less susceptible while the LPS group mutants were more susceptible than the wild-type. The MICs of chloramphenicol for the first-step ERN mutants were 12 mg/L and for the second-step ERN mutants they ranged from 24 to 64 mg/L. In the LPS group, chloramphenicol MICs were between 2 and 4 mg/L in all tested isolates. Similar trends were seen for erythromycin, but the opposite was observed for nitrofurantoin. All mutants containing inactivating lon mutations had lower nitrofurantoin MICs than the wild-type. In contrast, the majority of the LPS mutants had MICs of nitrofurantoin slightly higher than the wild-type. Half of the tested first-step mutants had tetracycline MICs as high as the wild-type strain DA5438, with the other half displaying one or two Etest steps higher MICs. The secondstep mutants showed slightly higher tetracycline MICs, reaching up to 4 mg/L. Tetracycline MICs were a few Etest steps different between ERN and LPS mutants. Neither kanamycin nor b-lactam MICs differed between the mutants and the wild-type strain. Ciprofloxacin MICs were somewhat higher in the LPS group as compared with the wild-type and were lower in lon mutants. In addition, variable ciprofloxacin MICs were seen in the ERN group.
Reconstructed mutants
The trends observed for the original mutants were similar in the reconstructed strains. Thus, a distinct division between ERN and LPS reconstructed mutations was observed for chloramphenicol and erythromycin MICs. For the former group they were increased and for the latter one they were decreased compared with isogenic wild-type controls. While b-lactam and ciprofloxacin MICs were elevated in the marR reconstructed strain, the lon mutant had a notable decrease in the ciprofloxacin MIC, a slight increase in the cefotaxime MIC and a wild-type value for the ampicillin MIC. The nitrofurantoin MIC in the reconstructed lon mutant was lower than in the wild-type, but slightly increased in the marR reconstructed strain. No significant MIC deviation from the wild-type strain was found for tetracycline and kanamycin. Reconstructed LPS mutants had a few steps higher MICs of cefotaxime and ciprofloxacin compared with the wild-type control. Tetracycline, kanamycin, ampicillin and nitrofurantoin MICs deviated from those for the wild-type by one Etest step or remained unchanged.
We also assessed the original mutant hypersusceptibility to novobiocin, which indicates impaired assembly of LPS, by inspecting the growth of mutants in the presence of novobiocin and Linkevicius et al. 
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Mechanisms of tigecycline resistance comparing them with the wild-type control. ERN group mutants were consistently growing to higher OD 600 values than the wildtype strain and the opposite was observed for LPS mutants (data not shown), confirming that LPS biosynthesis was impaired in the LPS group. The same tendencies were observed once the mutations of both groups were reconstructed in the wild-type background (data not shown).
Fitness of in vitro-selected and reconstructed mutants
Biological fitness for the first-and second-step mutants was measured as a relative exponential growth rate compared with the wild-type strain DA5438. Most of the mutants demonstrated fitness costs, ranging from 2% to 30% among the first-step mutants and from no cost to 32% in the second-step mutants Linkevicius et al.
( Table 2 ). On average, the fitness cost comparing first-and secondstep mutants between the ERN and LPS groups was higher in the LPS mutants. The second-step ERN mutants that acquired marR as a second mutation had comparatively higher fitness costs than those in which the second mutation was not identified or an inactivation of the acrR gene was found. Some fitness variation between different marR mutations was also observed. In order to investigate fitness in more detail, we looked at three different growth parameters in the reconstructed mutants: the lag phase, growth rates estimated from the exponential growth phase and the total yield (Figure 1 ). On average, the wild-type strain DA5438 had a lag phase of 59 min. The relative lag phase of the lon mutant was around 10% longer than the isogenic wild-type and LPS mutants demonstrated even longer lags: +18% for rfaC, +31% for rfaE and +20% for lpcA compared with their wild-type strain. In contrast, a shorter lag time (25%) was observed for the marR mutant (Figure 1a) . The exponential growth rates for all five mutants were lower than for the wild-type. The lon and marR mutants showed a 4% and 3% reduction in the growth rate, respectively. Even slower growth rates were found for the LPS group: 218% for rfaE and 29% for rfaC and lpcA mutants (Figure 1b) . Finally, relative total yield values were also lower for all five tested mutants (Figure 1c) . The ERN group mutations showed slightly smaller reductions compared with the isogenic wild-type: 29% for lon and 22% for marR. The LPS mutants demonstrated a larger difference: 218% for rfaC, 213% for rfaE and 215% for lpcA. Therefore, after evaluating all three growth parameters, we conclude that the lon, rfaC, rfaE and lpcA mutations were costly due to a prolonged lag phase, slower growth rate and reduced total yield, while the overall cost of the marR mutation was lower as the growth parameters were closer to those of the wild-type. All three of these growth parameters are likely to be important for establishing a successful infection and being able to compete with other bacteria within the population.
The reconstructed mutants were also characterized by performing a starvation assay in the stationary phase to further evaluate their fitness (Figure 2) . The tendencies among the isogenic wild-type controls and mutant strains remained fairly similar. The majority of strains on average had a higher viable count on the second day of the experiment, except the rfaE reconstructed mutant (Figure 2b) . A sharp drop in the bacterial count was observed for the marR mutant and the LPS group reconstructed mutants on day 4, while the cell count of the reconstructed lon mutant declined more slowly (Figure 2a and b) . On day 7, all strains reached bacterial counts close to zero. These assays did not reveal any obvious differences in starvation survival between the wild-type and mutants. Mechanisms of tigecycline resistance 2815 
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Relevance of target genes identified in vitro to the reduced susceptibility of tigecycline in clinical isolates
To determine whether mutations in the target genes identified in vitro were also involved in causing resistance in the clinical isolates, we compared the DNA/protein sequences of the target genes in the clinical isolates with those of the in vitro-selected mutants. When loss-of-function mutations (e.g. insertions and deletions) were found in the same target genes in both clinical isolates and mutants selected in vitro, they could unambiguously be identified as changes that inactivated the encoded protein and caused reduced susceptibility to tigecycline. However, the significance of amino acid substitutions to target protein function and the reduced susceptibility in clinical isolates was more difficult to assess. To resolve this, we examined the extent of amino acid sequence conservation of the identified target proteins by comparing 18 E. coli genomes obtained from NCBI. Target sequence alignments helped us recognize the conserved and the variable regions and only amino acid substitutions found in highly conserved parts of the target protein in the clinical isolates were considered as changes that could confer decreased susceptibility to tigecycline. Analysis of the whole-genome sequences of two clinical isolates showed that they harboured both insertions/deletions as well as amino acid substitutions in the conserved regions of the target proteins identified in the laboratory-selected E. coli strains (Table 4) . Both clinical strains contained ERN group mutations. DA21682 carried an IS186 insertion in the promoter region of the lon gene and amino acid substitution in AcrR. DA24486 had a loss-of-function deletion in the end of the MarR protein. Additionally, LPS group mutations were found in the DA21682 isolate. Although all heptose biosynthesis proteins were unchanged, the transporters of heptose residues RfaC and RfaF had acquired amino acid substitutions in highly conserved regions. These results strongly suggest that mutations in the target genes identified in mutants selected in vitro are also conferring resistance in the clinical isolates.
MICs and fitness of clinical isolates
The tigecycline MICs of the clinical isolates correlated well with the ones observed in our in vitro selection experiments (Tables 2 and 4) .
The values ranged from 0.094 to 0.38 mg/L, which mainly corresponded to the first-step selection mutants. We also measured the exponential growth rates of clinical isolates to evaluate their relative fitness. Six out of eight clinical isolates (DA21682, DA24439, DA24486, DA25177, DA26668 and DA26669) grew faster than our wild-type control strain (DA5438). On average, the doubling time for strain DA5438 was 20 min and faster-growing clinical isolates divided in 17-19 min. The remaining two clinical isolates (DA24516 and DA25176) had doubling times of 22 min. These results suggest that the relative exponential growth rates of mutants with reduced susceptibility to tigecycline can vary extensively (17-22 min generation times) and that they are similar in fitness to tigecycline-susceptible isolates (see Figure 2 in Sandegren et al.
45
). However, it should be noted that these comparisons are made between non-isogenic strains and that other genetic differences might obscure any effect of the mutations causing reduced tigecycline susceptibility.
Discussion
In this study, many different genes were identified to play a role in reduced susceptibility to tigecycline in E. coli mutants selected in vitro. We discovered loss-of-function mutations in Lon protease, which is responsible for the degradation of many regulatory proteins, including MarA. 46 Transcription of the latter is regulated by the local repressor MarR, 47, 48 which was also one of the targets for reduced susceptibility to tigecycline. MarA is one of the positive regulators of the AcrAB efflux system. 49 In addition, it also up-regulates micF, which causes down-regulation of the OmpF porin. 50 In other words, loss-of-function mutations in marR or lon would cause a higher concentration of MarA in the cell, which in turn would increase the efflux of tigecycline through the AcrAB-TolC system and decrease influx through OmpF. As marR-inactivating mutations have been found to occur throughout the coding sequence of the gene, 51 it is reasonable to assume that the marR amino acid substitutions observed in our study were also inactivating mutations. A combination of lon and marR mutations gave the highest tigecycline MICs during the selection experiments (Table 2) . Additionally, the local repressor AcrR is suggested to finetune the expression of the AcrAB efflux pump, preventing it from overexpression, which is toxic to the bacterial cell. 52 Mutations that inactivated acrR were also found in our selection experiments and would cause reduced susceptibility to tigecycline through increased expression of the AcrAB system. Our results are in accord with the previous reports where reduced susceptibility to tigecycline was linked to up-regulation of the AcrAB efflux pump in E. coli 12, 21 and other Gram-negative bacteria. 17 -20,22,53 The second distinct group of mutations, the LPS group, has not been described before in relation to reduced susceptibility to tigecycline. It included mutations in the heptose biosynthetic pathway and transport proteins transferring and incorporating heptose residues into the LPS inner-core structure. Heptose biosynthesis in E. coli is a process during which D-sedoheptulose 7-phosphate is transformed to ADP-L-b-D-heptose in five consequential enzymatic reactions. 54 The enzymes involved are LpcA (GmhA), RfaE [HldE (catalyses two steps)], GmhB and RfaD (HldD). We found mutations in lpcA and rfaE that would cause amino acid substitutions and an inactivating mutation in rfaD. Disruption of any step in this pathway would prevent incorporation of Linkevicius et al.
the heptose residues in the LPS structure. We also found inactivating mutations in the rfaC (waaC) and rfaF (waaF) genes, which encode proteins that transfer the first and second heptose residues, respectively, and integrate them in the inner core of LPS. Interruption of biosynthesis or transport of heptose causes a heptoseless phenotype called 'deep-rough'. 55 The 'deep-rough' mutant LPS structure is unstable due to the lack of negatively charged phosphate groups on heptose residues, which normally stabilize the structure through the interaction with positive ions. Furthermore, the 'deep-rough' phenotype leads to increased susceptibility to hydrophobic compounds (e.g. novobiocin), leakiness of the outer membrane to periplasmic proteins, .90% reduced expression of porins (e.g. OmpF) and induced production of colanic acid leading to a mucoid phenotype. 55 Although the actual mechanism of tigecycline influx into the cell is not known, it is assumed that it follows the general pathway of other tetracyclines through OmpF and OmpC porins. A slow rate of diffusion of lipophilic tetracyclines through the outer membrane has been proposed as an additional way of entrance, especially if the porin expression on the surface is low. 56 Thus, combination of the high lipophilicity of tigecycline and the properties of the 'deep-rough' phenotype could be assumed to make the mutants more susceptible to tigecycline. However, we observed the opposite. The mutants with LPS mutations exhibited reduced susceptibility to the antibiotic. Possibly, the 'deep-rough' mutants obtained during our selections could have caused a significant reduction of porins in the outer membrane. As a result, the slow rate porin-independent diffusion of tigecycline through the outer membrane was not enough to cause a sufficiently high level of intracellular tigecycline to inhibit protein synthesis.
It is intriguing that among the second-step LPS mutants, there were a few strains where we could not identify a possible subsequent mutation that would cause the increase in the tigecycline MIC. As was described previously, duplications containing the AcrAB system genes are frequent but unstable changes in the chromosome of E. coli. 43, 44 Thus, it is possible that they could have segregated during the growth of mutants without the selective pressure of tigecycline during preparation of the genome for sequencing.
Although we were not able to select for E. coli mutants in vitro with clinical resistance to tigecycline, the mutation rate of reduced susceptibility to tigecycline was relatively high, explainable by the large number of target genes whose inactivation resulted in an increased tigecycline MIC. Moreover, the susceptibility to tigecycline decreased gradually with each selection step. Therefore, it is possible that even higher MICs of tigecycline, comparable to clinically resistant isolates, could be reached if other first-step mutants with different first-step mutations were chosen for selection experiments. Furthermore, the majority of our selected and reconstructed mutants demonstrated a substantial fitness cost. The exponential growth rates measured for the first-and second-step mutants were lower than those of the parental strain, with the second-step mutants showing the highest cost. Similar trends were seen for the reconstructed mutations, where we observed not only slower growth rates, but in the majority of cases also a longer lag phase and lower total yield. The reduced fitness of these mutants suggests that they might have difficulty in establishing a successful infection. Similar consequences of fitness cost were observed in our previous studies while characterizing fosfomycin 57 and nitrofurantoin 45 mutants and their ability to cause urinary tract infections. Nevertheless, in vivo studies in animal models are needed to be able to better evaluate the fitness effects. Our cross-resistance data revealed a few trends. The MICs of antibiotics with hydrophobic properties confirmed the division of mutants into the ERN and LPS groups. This was also in agreement with the novobiocin hypersusceptibility testing. The MICs of the hydrophobic drugs were higher for the ERN group compared with the wild-type control, because these antibiotics are the substrates of the multidrug efflux pump AcrAB 58 and mutations in lon, marR and acrR cause up-regulation of the AcrAB system and subsequent increases in the MICs of hydrophobic drugs. The hydrophobic antibiotics had an opposite effect on LPS mutants with impaired heptose biosynthetic pathway. They had reduced MICs for chloramphenicol and erythromycin, and slower growth in novobiocinsupplemented medium compared with the wild-type. These are typical features of 'deep-rough' mutants. 55 Another interesting trend observed was reduced MICs of ciprofloxacin and nitrofurantoin in loss-of-function lon mutants. These antibiotics act by damaging DNA and inducing the SOS response. 59 -61 SulA, which is the inhibitor of FtsZ, stops the division of the cell during the SOS response to allow repair of DNA damage. Additionally, SulA is a substrate of the Lon protease. Therefore, loss-of-function mutations in the lon gene of the mutants with reduced susceptibility to tigecycline would have the SulA protein stabilized and an irreversible inhibition of cell division would make lon mutants more susceptible to ciprofloxacin and nitrofurantoin than the wild-type control strain, explaining the lower MICs. Cross-resistance between ciprofloxacin and tigecycline was previously reported in clinical E. cloacae and was associated with overexpression of the AcrAB pump. 53 Similarly, the MICs of ciprofloxacin for our selected mutants that up-regulated the AcrAB system were also elevated.
Analysis of two whole-genome-sequenced clinical E. coli isolates that demonstrated reduced susceptibility to tigecycline comparable to our in vitro-selected mutants revealed mutations in the same target genes. While several mutations from both the ERN and LPS groups were identified in one clinical isolate, the second clinical E. coli mutant carried a deletion of 109 bp in marR. It is highly likely that these mutations played a role in increasing the MIC of tigecycline by the mechanisms discussed above, because the mutations observed were either loss-of-function changes or amino acid substitutions in highly conserved regions. In addition, it is interesting to note that a combination of both groups of mutations was observed not only in one of the clinical isolates, but also in the second-step in vitro mutants. In these mutants the first-step mutation was found in the lpcA gene (LPS group), and was followed by a duplication containing the genes for the AcrAB pump (ERN group), as a second mutation.
In conclusion, eight target genes mutated with relatively high mutation rates during our laboratory selection experiments to cause reduced susceptibility to tigecycline. However, these mutants had relatively low-level resistance and a high fitness cost. The potential reduction of the risk of infection by a combination of low resistance and high cost needs to be addressed by animal experiments to determine whether mutants with high resistance can successfully be selected and established within a host. Furthermore, experiments are needed to determine whether and how the fitness costs associated with these different mutation types can be ameliorated by compensatory mutations.
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